Donanemab (Donanemab) indication scope and main diseases treated

Donanemab (Donanemab) is a new type of anti-β-amyloid monoclonal antibody that mainly targets the modified form of Aβ protein - sulfotyrosine42 amyloid beta (pGlu3-Aβ) is designed to remove amyloid plaques deposited in the brains of patients with Alzheimer's disease, thereby delaying the progression of the disease. The drug's current core indication is early-stage Alzheimer's disease, especially patients with mild cognitive impairment and mild Alzheimer's disease stages.

In clinical studies, donenezumab has shown positive efficacy, especially in the TRAILBLAZER-ALZ 2 study, which showed that it can significantly slow down the decline in cognitive function and daily behavioral abilities in patients with Alzheimer's disease. There were statistically significant improvements in multiple cognitive score scales in the donenemab treatment group compared with placebo. This makes donelenumab considered to be another breakthrough anti-Aβ-targeted drug after lerinumab (Lecanemab) and aducanumab (Aducanumab).

Currently, donenemab has not been widely marketed globally, but it has obtained fast track status in the United States and is in the FDA review process. Although it has not yet received universal approval, its clear indication is still for patients with confirmed Alzheimer's disease and proven amyloid pathology. Therefore, before starting treatment, it is usually necessary to confirm the presence of Aβ deposition in patients through PET imaging or cerebrospinal fluid biomarkers to ensure the accuracy and efficacy of the drug.

Although donelenumab has promising therapeutic prospects, it may also cause adverse reactions similar to other anti-Aβ antibodies, such as amyloid-related imaging abnormalities (ARIA), including cerebral edema or minor bleeding. Therefore, use of this drug requires regular imaging monitoring and risk assessment. Overall, donexumab represents the latest advancement in the treatment of Alzheimer's disease and is expected to provide more effective disease-modifying treatments for early-stage patients in the future.

Reference materials:https://www.drugs.com/donanemab.html